Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Høyfermentert matintervensjon blant lokalt avanserte rektalkreftpasienter (FEED Trial)

En randomisert høyfermentert matintervensjon blant lokalt avanserte rektalkreftpasienter (FEED Trial)

The purpose of the study is to evaluate the feasibility and acceptability of a dietary intervention (FEED-FF) that includes fermented foods (FF), among locally advanced rectal cancer patients and non-small cell lung cancer (NSCLC) patients, and to explore whether this diet can improve outcomes in rectal cancer patients receiving chemoradiation and NSCLC patients receiving immunotherapy.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Studietype

Intervensjonell

Registrering (Faktiske)

39

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Florida
      • Tampa, Florida, Forente stater, 33612
        • Moffitt Cancer Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria for GI Patients:

  • 18 years of age or older
  • Diagnosed with locally advanced rectal cancer (Stage II-III)
  • Will undergo neoadjuvant chemoradiation at Moffitt Cancer Center
  • Able to pick up FFs once/weekly at Moffitt
  • Able to speak and read English
  • Able to consume foods orally
  • Able to provide informed consent

Inclusion Criteria for Thoracic Patients:

  • 18 years of age or older
  • Diagnosed with stage II-IV non-small cell lung cancer (NSCLC)
  • Will undergo Immunotherapy with immune checkpoint inhibitors (+/- chemotherapy or other treatment) at Moffitt Cancer Center
  • Able to pick up FFs once/weekly at Moffitt
  • Able to speak and read English
  • Able to consume foods orally
  • Able to provide informed consent

Exclusion Criteria:

  • Antibiotic use within 1 month prior to baseline
  • If currently using probiotics, unwillingness to cease probiotic use
  • Previous receipt of surgery, immunotherapy, chemotherapy, or radiation for a colon or rectal tumor
  • Per clinician's discretion, clinician confirmed inflammatory bowel conditions (e.g., ulcerative colitis, Crohn's disease)
  • Infectious disease diagnosed <1 month prior to baseline
  • Already consuming ≥2 servings of fermented foods/day
  • Previously diagnosed with a mast cell disorder or histamine allergy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: FEED-FF

Participants will be asked to pick up the fermented foods at the Research Kitchen at Moffitt. Participants will be asked to eat 3-6 servings of FFs per day, from 1 week prior to treatment start through 12 weeks after treatment start/until the restaging scope is completed.

At baseline, the end of week 6.5 and again at week 12.5, participants will be asked to provide biospecimens including a stool sample collected at home and a blood specimen collected in clinic.

Participants will be asked to complete a food frequency questionnaire, a quality-of-life survey, two symptom related surveys, and a stool collection questionnaire at these same timepoints.

After the dietary intervention, participants will be asked to complete an exit survey to provide feedback on the study and intervention.

3-6 servings of any combination of the following fermented foods/day (from 1 week prior to treatment to approximately 12 weeks after the start of treatment): Yogurt, cottage cheese, kefir, kombucha, sauerkraut, and kimchi.

Aktiv komparator: Standard of Care (SUC)

Participants will receive general healthy eating handouts similar to current usual care documents provided in clinic.

These handouts will detail typical healthy foods and the suggested level of intake, or servings per day.

At baseline, the end of week 6.5 and again at week 12.5, participants will be asked to provide biospecimens including a stool sample collected at home and a blood specimen collected in clinic. Participants will be asked to complete a food frequency questionnaire, a quality-of-life survey, two symptom related surveys, and a stool collection questionnaire at these same timepoints.

Standard of Care (SUC) is the treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by health care professionals. Standard of Care will comprise general healthy eating handouts that describe typical healthy foods and the suggested level of servings per day.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Effects of the FEED-FF diet on clinical response to chemoradiation (Rectal Cancer Patients)
Tidsramme: At Baseline and Up to 12.5 Weeks

Clinical response measured in clinic by MRI/Endoscopy/Digital rectal exam, comparing the FEED-FF arm to SUC arm.

Indicators of clinical response are Complete Response, Near Complete Response, Incomplete Response, or Progressive Disease.

At Baseline and Up to 12.5 Weeks
Effects of the FEED-FF diet on clinical response to immunotherapy (Lung Cancer Patients)
Tidsramme: At Baseline and Up to 12.5 Weeks

Clinical benefit to immune checkpoint inhibitor therapy will be measured in clinic by MRI/Endoscopy, comparing the FEED-FF arm to SUC arm.

Defined as the best response of complete tumor resolution (CR), Partial Response (PR), and stable tumor size (SD) within 12 months.

Progressive Disease (PD) within 12 months indicates no clinical benefit.

At Baseline and Up to 12.5 Weeks
Effects of FEED-FF diet on the gut microbiome
Tidsramme: At Baseline, Week 6.5 and Up to 12.5 Weeks

Measured by fecal biospecimen sample collection; FEED-FF arm hypothesized to demonstrate increases in short chain fatty acid (SCFA) producing bacteria and higher alpha diversity compared to SUC arm.

At Baseline, Week 6.5 and Up to 12.5 Weeks
Effects of FEED-FF diet on local immune-related biomarkers
Tidsramme: At Baseline and Up to 12.5 Weeks

Measured by FFPE tissue slides; FEED-FF arm hypothesized to demonstrate enhanced immune response such as higher T-cell expression compared to SUC arm.

At Baseline and Up to 12.5 Weeks
Effects of FEED-FF diet on quality of life
Tidsramme: At Baseline, Week 6.5 and Up to 12.5 Weeks

Measured by using the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Survey; FEED-FF arm hypothesized to demonstrate more favorable QoL compared to SUC arm.

At Baseline, Week 6.5 and Up to 12.5 Weeks
Efficacy of the FEED-FF intervention
Tidsramme: At Baseline, Week 6.5 and Up to 12.5 Weeks

Measured by an accrual rate of 50% of eligible patients, fermented foods (FF) intake of at least 3 servings on at least 80% of days, and at least 80% of intervention group reporting high/very high satisfaction with intervention.

Weekly goal adherence via randomly administered food logs, tracking responses to and general completion of an exit survey will be utilized.

At Baseline, Week 6.5 and Up to 12.5 Weeks
Feasibility of the FEED-FF intervention
Tidsramme: At Baseline, Week 6.5 and Up to 12.5 Weeks

Measured by an accrual rate of 50% of eligible patients, fermented foods (FF) intake of at least 3 servings on at least 80% of days, and at least 80% of intervention group reporting high/very high satisfaction with intervention.

Weekly goal adherence via randomly administered food logs, tracking responses to and general completion of an exit survey will be utilized.

At Baseline, Week 6.5 and Up to 12.5 Weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Doratha (Armen) Byrd, PhD, MPH, Moffitt Cancer Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. april 2024

Primær fullføring (Faktiske)

2. juli 2026

Studiet fullført (Antatt)

1. januar 2027

Datoer for studieregistrering

Først innsendt

18. mars 2024

Først innsendt som oppfylte QC-kriteriene

22. mars 2024

Først lagt ut (Faktiske)

29. mars 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere